T1	CHEM 56 66	BMS-986178
#1	AnnotatorNotes T1	C4287779; anti-OX40 antibody BMS 986178; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	PROC 70 81	monoterapia
#2	AnnotatorNotes T2	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T3	CHEM 103 112	nivolumab
#3	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 117 127	ipilimumab
#4	AnnotatorNotes T4	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	DISO 131 146	tumores sólidos
#5	AnnotatorNotes T5	C0280100; Solid Neoplasm; Neoplastic Process
T6	PROC 177 194	Estudio fase 1/2a
T7	PROC 225 236	monoterapia
#6	AnnotatorNotes T7	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T8	CHEM 258 267	nivolumab
#7	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 270 280	ipilimumab
#8	AnnotatorNotes T9	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	DISO 284 299	tumores sólidos
#9	AnnotatorNotes T10	C0280100; Solid Neoplasm; Neoplastic Process
T11	DISO 331 346	Tumores sólidos
#10	AnnotatorNotes T11	C0280100; Solid Neoplasm; Neoplastic Process
T12	PROC 439 447	terapias
#11	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	PROC 534 546	tratamientos
#12	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	DISO 679 693	lesión medible
T15	CHEM 198 208	BMS-986178
#13	AnnotatorNotes T15	C4287779; anti-OX40 antibody BMS 986178; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	PROC 720 723	TAC
#14	AnnotatorNotes T16	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T17	PROC 725 755	tomografía axial computarizada
#15	AnnotatorNotes T17	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T18	PROC 759 762	MRI
#16	AnnotatorNotes T18	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T19	PROC 764 797	imágenes por resonancia magnética
#17	AnnotatorNotes T19	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T20	DISO 925 935	Metástasis
#18	AnnotatorNotes T20	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T21	ANAT 951 975	sistema nervioso central
#19	AnnotatorNotes T21	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T22	ANAT 978 1002	sistema nervioso central
#20	AnnotatorNotes T22	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T23	DISO 1030 1040	enfermedad
#21	AnnotatorNotes T23	C0012634; Disease; Disease or Syndrome
T24	DISO 1043 1053	Neoplasias
#22	AnnotatorNotes T24	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T25	DISO 1070 1091	Enfermedad autoinmune
#23	AnnotatorNotes T25	C0004364; Autoimmune Diseases; Disease or Syndrome
T26	DISO 1123 1148	Enfermedad cardiovascular
#24	AnnotatorNotes T26	C0007222; Cardiovascular Diseases; Disease or Syndrome
T27	PROC 1181 1194	Cirugía mayor
#25	AnnotatorNotes T27	C0679637; major surgery; Therapeutic or Preventive Procedure
T28	DISO 424 436	intolerantes
#26	AnnotatorNotes T28	C0277585; Intolerance to drug; Pathologic Function
T29	PROC 849 859	evaluación
#27	AnnotatorNotes T29	C1261322; Evaluation procedure; Health Care Activity
T30	DISO 876 891	tumores sólidos
#28	AnnotatorNotes T30	C0280100; Solid Neoplasm; Neoplastic Process
T31	ANAT 1134 1148	cardiovascular
#29	AnnotatorNotes T31	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T32	Date 13 17	2015
T33	LIVB 384 393	pacientes
#30	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	LIVB 493 502	pacientes
#31	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T36	LIVB 629 636	Hombres
#32	AnnotatorNotes T36	C0025266; Male population group; Population Group
T37	LIVB 639 646	mujeres
#33	AnnotatorNotes T37	C0043210; Woman; Population Group
T38	Age 650 663	18 años o más
T39	Spec_cue 1110 1120	sospechada
T41	Duration 1216 1234	menos de 4 semanas
A1	Assertion T25 Speculated
A2	Status T20 History_of
A3	Status T27 History_of
A4	Status T25 History_of
#34	AnnotatorNotes T14	C5238366; Measurable Lesion; Finding 
T35	Neg_cue 507 509	no
T40	Observation 515 568	candidatos a otros tratamientos con beneficio clínico
A5	Assertion T40 Negated
T42	Quantifier_or_Qualifier 1168 1178	controlada
A6	Assertion T42 Negated
T43	Neg_cue 1165 1167	no
R1	Negation Arg1:T35 Arg2:T40	
R2	Negation Arg1:T43 Arg2:T42	
R3	Location_of Arg1:T31 Arg2:T26	
R4	Speculation Arg1:T39 Arg2:T25	
R5	Location_of Arg1:T21 Arg2:T20	
R6	Location_of Arg1:T22 Arg2:T20	
T44	Observation 1017 1040	fuente de la enfermedad
#35	AnnotatorNotes T44	C0449422; Source of disease; Finding
R7	Location_of Arg1:T22 Arg2:T44	
R8	Location_of Arg1:T21 Arg2:T44	
T45	Quantifier_or_Qualifier 1011 1016	única
R9	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T45	
R10	Location_of Arg1:T22 Arg2:T23	
R11	Location_of Arg1:T21 Arg2:T23	
T46	Quantifier_or_Qualifier 1092 1098	activa
#36	AnnotatorNotes T46	C0679217; Active State; Idea or Concept
R12	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T46	
T47	Quantifier_or_Qualifier 1149 1162	significativa
#37	AnnotatorNotes T47	C1546944; Event Seriousness - Significant; Qualitative Concept
R13	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T47	
T48	Quantifier_or_Qualifier 1054 1067	concomitantes
#38	AnnotatorNotes T48	C0521115; Simultaneous; Temporal Concept
R14	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T48	
R15	Used_for Arg1:T1 Arg2:T2	
R16	Combined_with Arg1:T1 Arg2:T3	
R18	Combined_with Arg1:T1 Arg2:T4	
R19	Used_for Arg1:T15 Arg2:T7	
R17	Combined_with Arg1:T15 Arg2:T8	
R20	Combined_with Arg1:T15 Arg2:T9	
T49	Quantifier_or_Qualifier 147 156	avanzados
#39	AnnotatorNotes T49	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
T50	Quantifier_or_Qualifier 300 309	avanzados
#40	AnnotatorNotes T50	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
T51	Quantifier_or_Qualifier 347 356	avanzados
#41	AnnotatorNotes T51	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R21	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T51	
R22	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T50	
R23	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T49	
R24	Experiences Arg1:T33 Arg2:T28	
R25	Causes Arg1:T12 Arg2:T28	
T52	Observation 409 421	refractarios
#42	AnnotatorNotes T52	C0438286; Absent response to treatment; Finding
R26	Experiences Arg1:T33 Arg2:T52	
T53	Observation 464 481	beneficio clínico
R27	Causes Arg1:T12 Arg2:T53	
R28	Experiences Arg1:T34 Arg2:T52	
R29	Overlap Arg1:T52 Arg2:T12	
R30	Experiences Arg1:T34 Arg2:T28	
R31	Experiences Arg1:T34 Arg2:T12	
R32	Experiences Arg1:T34 Arg2:T13	
R33	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T40	
T54	Result_or_Value 623 626	0-1
T55	CONC 581 585	ECOG
#44	AnnotatorNotes T55	C1520224; ECOG performance status; Intellectual Product
T56	CONC 587 621	Eastern Cooperative Oncology Group
#45	AnnotatorNotes T56	C1520224; ECOG performance status; Intellectual Product
R34	Has_Result_or_Value Arg1:T56 Arg2:T54	
R35	Has_Result_or_Value Arg1:T55 Arg2:T54	
R36	Has_Age Arg1:T37 Arg2:T38	
R37	Has_Age Arg1:T36 Arg2:T38	
T57	Quantifier_or_Qualifier 666 678	Al menos una
R38	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T57	
T58	CONC 697 715	inicio del estudio
#46	AnnotatorNotes T58	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R39	Overlap Arg1:T14 Arg2:T58	
R43	Overlap Arg1:T16 Arg2:T58	
R44	Overlap Arg1:T17 Arg2:T58	
R45	Overlap Arg1:T18 Arg2:T58	
R46	Overlap Arg1:T19 Arg2:T58	
T59	CONC 818 834;893 897	criterios RECIST v1.1
#47	AnnotatorNotes T59	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
T60	CONC 836 891	Criterios de evaluación de respuesta en tumores sólidos
#48	AnnotatorNotes T60	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
R48	Overlap Arg1:T27 Arg2:T41	
T61	CONC 1244 1262	iniciar el estudio
#49	AnnotatorNotes T61	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R49	Before Arg1:T27 Arg2:T61	
R50	Causes Arg1:T23 Arg2:T20	
R51	Experiences Arg1:T33 Arg2:T12	
R52	Experiences Arg1:T33 Arg2:T53	
R53	Experiences Arg1:T34 Arg2:T53	
#43	AnnotatorNotes T53	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R54	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T40	
R40	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T42	
#50	AnnotatorNotes T45	C0205171; Singular; Quantitative Concept
A7	Experiencer T33 Patient
A8	Experiencer T34 Patient
A9	Experiencer T37 Patient
A10	Experiencer T36 Patient
